Thrombotic microangiopathy (TMA) is a serious complication of BMT. Several factors are important in the etiology of TMA, such as cyclosporin A, GVHD, irradiation, intensive conditioning chemotherapy and infection, which cause damage to vascular endothelial cells leading to activation of these cells. We describe two young children with TMA following high-dose chemotherapy with autologous BMT. Development of TMA was accompanied by reactivation of HHV-6, which was identified by both an increase in the copy number of HHV-6 DNA in the peripheral blood and a significant increase in antibody titers to HHV-6. Thus, it was suggested that reactivation of HHV-6 together with highdose chemotherapy played an important role in the pathogenesis of TMA in these patients. Since HHV-6 is known to infect vascular endothelial cells, and CMV which is virologically closely related to HHV-6, has been reported to be a pathogen that causes TMA, infection with HHV-6 of vascular endothelial cells may induce TMA via damage and activation of these cells.
and thus leads to TMA, is CMV. Human herpesvirus 6 (HHV-6), which is closely related to CMV, is known to infect lymphocytes, monocytes/macrophages, and vascular endothelial cells. Primary infection of HHV-6 generally occurs in early childhood, mainly causes exanthem subitum and is associated with sero-conversion to positive antibody status. 5 As with other herpesviruses, HHV-6 manifests persistent and latent infection in the salivary glands, lymph nodes, kidney and liver. It can be reactivated under conditions of immunosuppression and often causes significant clinical diseases including interstitial pneumonitis, delay or suppression of marrow engraftment and encephalitis following BMT. [6] [7] [8] [9] [10] [11] Thus, HHV-6 plays a significant pathogenic role in the development of complications after BMT. We documented HHV-6 reactivation in two young children with TMA after autologous BMT for advanced solid tumors and leukemia. In these patients, development of TMA was accompanied by a significant increase in the copy number of HHV-6 DNA in peripheral blood mononuclear cells (PMNCs) and an increase in antibody titers to HHV-6, suggesting that reactivation of HHV-6 contributed to the development of TMA in these patients.
Patients and methods
A 14-month-old girl and a 16-month-old boy with hepatoblastoma and acute megakaryocytic leukemia, respectively, underwent autologous BMT. Patient characteristics are summarized in Table 1 . Neither patient received radiotherapy.
The diagnosis of BMT-associated TMA was based on the presence of fragmented erythrocytes, hemolytic anemia, consumptive thrombocytopenia, and renal failure. The grade of TMA was assessed based on the Zeigler ZR grading system. taken. For prophylaxis of herpes simplex infection, acyclovir (ACV) was begun before initiation of the conditioning regimen. She received no administration of intravenous immunoglobulin. After transplantation she received G-CSF (200 g/m 2 ) daily and neutrophil counts increased to 0.5 × 10 9 /l on day 10. However, signs of microangiopathic hemolysis including microscopic hematuria and granular casts, elevated serum levels of LDH (704 U/l) and creatinine (0.4 mg/dl) and decreased serum levels of haptoglobin (Ͻ4.0 mg/dl) became marked on day 14 ( Figure 1 ). Her platelet count dropped below 5.0 × 10 4 /l. Peripheral blood smears revealed erythrocyte fragmentation. Prothrombin time (76%) and activated partial thromboplastin time (39 s) were within normal limits, but the concentration of thrombin-antithromboplastin complex was elevated. Hypertension with deterioration of renal function were encountered. Since diffuse interstitial infiltration on chest radiography appeared, ganciclovir (GCV) (10 mg/kg) was empirically started on day 15 because of possible CMV pneumonitis. Bone marrow suppression occurred due to GCV, so G-CSF was administered. With the increase in neutrophil counts, ascites became marked and her clinical course deteriorated markedly with rapid onset of respiratory and cardiac insufficiency requiring mechanical ventilation, as well as aggressive transfusion requirement for her hemolytic anemia and thrombocytopenia. The clinical diagnosis of TMA was made. Administration of dipyridamole and prostaglandin derivatives including PGE 2 and PGI 2 were not effective. Plasma exchange and hemodialysis were repeatedly undertaken for 3 days. After 4 days, the amount of pleural effusion and ascites decreased and mechanical ventilation was stopped. Hemolysis disappeared 60 days after BMT and she was discharged on day 105.
Patient 2:
A 16-month-old boy was diagnosed as having acute megakaryocytic leukemia. Since achievement of complete remission had been delayed, he underwent autologous BMT during 1st complete remission. ACV was administered for prophylaxis of herpes simplex infection. No intravenous immunoglobulin was administered. After transplantation, he received 300 g/m 2 of G-CSF daily and neutrophil counts increased to 0.5 × 10 9 /l on day 18. However, on day 16, severe thrombocytopenia with accelerated consumption of transfused platelets was observed. On day 19, chest radiography showed bilateral interstitial fluid retention with increased serum levels of BUN (26 mg/dl) and LDH (829 U/l), decreased serum haptoglobin levels (Ͻ4.0 mg/dl), and abnormal urinalysis with microscopic hematuria, severe proteinuria and granular casts (Figure 2) .
A review of the peripheral blood revealed erythrocyte fragmentation and a clinical diagnosis of TMA was made. Hypertension, fever, and pulmonary complaints of cough wheezing on exertion and tachypnea occurred. GCV was started empirically on day 19, for possible CMV pneumonitis. On day 30, echocardiography revealed cardiac dilatation and insufficiency. Dipyridamole, PGE 2 , PGI 2 and transfusion of fresh frozen plasma were not effective. Hemolysis, however, gradually improved and completely disappeared by day 56. Complete remission has been maintained for 3 years after BMT.
Analysis of human herpesvirus-6 and cytomegalovirus
For detection of HHV-6 DNA and CMV, amplification of viral DNA extracted from PMNCs was performed by PCR as previously described. 12, 13 The number of copies of viral genome per 10 5 PMNCs was estimated based on the semiquantative PCR and expressed as follows: (1+): 1 to 10 copies; (2+): 10 to 10 2 copies; (3+): 10 2 to 10 3 copies; (4+): more than 10 3 copies. Virus isolation was attempted from blood. Procedures for the isolation and the identification of HHV-6 and CMV were as previously described. 14 Specific antibody titers to HHV-6 were determined by an immunofluorescent antibody as described previously.
14,15 Plasma specimens were collected and frozen for serologic analyses. A change in the titer was considered significant if there was a four-fold increase from a baseline titer determined before BMT. IgG and IgM antibody titers to CMV were measured by enzyme immunoassay (Dade Behring, Marburg, Germany). A significant increase in CMV titers was defined by detection of specific IgM or elevation of specific IgG. Isolation of viruses from blood, more than 10 2 -fold increase in the copy number of viral DNA in PMNCs, or a significant increase in specific antibody titers was considered evidence for HHV-6 or CMV reactivation, respectively. The detection of IgM antibody for CMV was also considered evidence of CMV reactivation.
Results
Both patients with a history of exanthem subitum were seropositive for HHV-6 before BMT. No HHV-6 DNA was detected before day 0. HHV-6 DNA was concomitantly detected in PMNCs from both patients on days 15 (copy number: 2+) and 13 (copy number: 3+), respectively. In patient 1, a significant increase in antibody titers for HHV-6 and detection of HHV-6 DNA was accompanied by the onset of TMA (day 14). In patient 2, HHV-6 DNA was detected on day 13 with a concomitant increase in antibody titers for HHV-6 followed by the onset of TMA on day 16 (Table 2) . In patient 1, after the administration of GCV, HHV-6 DNA became undetectable in PMNCs and HHV-6 antibody titers decreased along with improvement of clinical symptoms (Figure 1) . In patient 2, HHV-6 DNA was repeatedly detected irrespective of the administration of GCV (2+ෂ4+), probably due to transient interruption and a small dose of GCV. However, the copy number of HHV-6 DNA decreased to 2+, and antibody titers gradually decreased with the recovery from TMA (Figure 2) . Patient 1 was seronegative for CMV and CMV DNA was not detected during her clinical course. Patient 2 was seropositive for CMV. Neither IgM antibody nor a significant increase in IgG antibody titers for CMV or CMV DNA was detected. Neither HHV-6 nor CMV was isolated from PBMCs from either patient.
Discussion
TMA is a well-recognized disorder following BMT. Damage and/or activation of vascular endothelial cells, leading to platelet activation and alterations in prostaglandin metabolism and the coagulation profile play a central role in the initiation of TMA. [16] [17] [18] Factors with a potential to cause endothelial cell damage, such as viral infection, intensive multiagent chemotherapy and irradiation, are responsible for TMA. 3, 4, 19 Prior to autologous BMT, patient 1 received cisplatin and cyclophosphamide. In addition to high-dose alkylating agents administered as conditioning which have potent effects on the vascular endothelium, these agents may also play some role in the pathogenesis of TMA.
Another possible cause of the initiation of TMA in our patients was HHV-6 infection. Reactivation of HHV-6 was observed at the time of TMA onset. In patient 1, after the administration of GCV, TMA abated, when HHV-6 DNA became undetectable and antibody titers to HHV-6 decreased. Although HHV-6 DNA was persistently detected in patient 2, the patient recovered from TMA with a decrease in antibody titers. In our prior study on HHV-6 infection in a large number of patients with BMT, detection of HHV-6 DNA was found to be accompanied by an increase in antibody titers.
Infection with CMV, which is closely related to HHV-6, 20, 21 was shown to contribute to the development of TMA. CMV infection in renal allograft recipients can cause distinctive glomerulopathy characterized by endothelial damage and mononuclear cell infiltration of glomerular capillaries. 22 Moreover, in patients with human immnodeficiency virus infection, TMA has been reported to be induced by CMV infection. 23 Endothelial CMV inclusions were confirmed by histological examination of the kidney in that study. Similarly, HHV-6 antigens were detected in the endothelial cells of small vessels in the brain in a patient with HHV-6 encephalitis. 24 It is therefore possible that reactivated HHV-6 infected endothelial cells which were subsequently injured and activated. Although no histological evidence of HHV-6 infection of endothelial cells was obtained, the development of TMA in our patients may be related to HHV-6 reactivation after BMT. In younger children, high levels of latent HHV-6 exist after primary infection during infancy. Therefore, reactivation of HHV-6 and the incidence of complications associated with it may be more frequent in young children than in adults. Previous studies on HHV-6 infection in BMT recipients have indicated that the virus causes interstitial pneumonia, bone marrow suppression and encephalitis. [6] [7] [8] [9] [10] [11] Our study has added TMA to the list of complications caused by reactivation or infection of HHV-6.
